Lv52
1188 积分 2022-10-24 加入
Abstract LB525: Discovery and characterization of ABSK111, a selective, CNS-penetrable, and broad-spectrum EGFR inhibitor targeting exon20 insertion, atypical and extracellular mutations
14天前
已关闭
Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights
1个月前
已完结
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
1个月前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
1个月前
已完结
Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models
1个月前
已关闭
-Omics potential of in vitro skin models for radiation exposure
1个月前
已完结
The evolving landscape of obesity pharmacotherapy
1个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
2个月前
已完结
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
2个月前
已完结
Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
2个月前
已完结
皖公网安备34019202002308
